Iberdomide is a cereblon modulator, which leads to the ubiquitination and degradation of both Ikaros and Aiolos and reduced CD19- and CD20-positive B cell numbers and type 1 interferon gene expression in SLE patients, while increasing regulatory T cell counts and serum interleukin-2 levels, pointing toward a reshaping of the function of the immune system (83). The gene discussed is IL2; the disease is systemic lupus erythematosus.